Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor.

PubWeight™: 2.37‹?› | Rank: Top 2%

🔗 View Article (PMID 10764421)

Published in J Clin Oncol on April 01, 2000

Authors

L E Spitler1, M L Grossbard, M S Ernstoff, G Silver, M Jacobs, F A Hayes, S J Soong

Author Affiliations

1: Northern California Melanoma Center, San Francisco, CA, USA. lynn@drspitler.com

Articles citing this

Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. J Clin Oncol (2011) 3.40

Systemic effects of local radiotherapy. Lancet Oncol (2009) 2.97

Effect of granulocyte/macrophage colony-stimulating factor on circulating CD8+ and CD4+ T-cell responses to a multipeptide melanoma vaccine: outcome of a multicenter randomized trial. Clin Cancer Res (2009) 1.90

Immunotherapy for melanoma: current status and perspectives. J Immunother (2010) 1.72

Immunogenicity and antitumor effects of vaccination with peptide vaccine+/-granulocyte-monocyte colony-stimulating factor and/or IFN-alpha2b in advanced metastatic melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696. Clin Cancer Res (2009) 1.71

A phase 2 trial of complete resection for stage IV melanoma: results of Southwest Oncology Group Clinical Trial S9430. Cancer (2011) 1.66

Inflammation driven by tumour-specific Th1 cells protects against B-cell cancer. Nat Commun (2011) 1.49

Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers. Br J Cancer (2004) 1.43

Current status of granulocyte-macrophage colony-stimulating factor in the immunotherapy of melanoma. J Immunother Cancer (2014) 1.33

Effect of granulocyte/macrophage colony-stimulating factor on vaccination with an allogeneic whole-cell melanoma vaccine. Clin Cancer Res (2009) 1.17

New insights into the role of the immune microenvironment in breast carcinoma. Clin Dev Immunol (2013) 1.01

Adjuvant GM-CSF improves survival in high-risk stage iiic melanoma: a single-center Study. Am J Clin Oncol (2014) 0.95

Site-specific PEGylation of engineered cysteine analogues of recombinant human granulocyte-macrophage colony-stimulating factor. Bioconjug Chem (2005) 0.94

Immunotherapy for prostate cancer: biology and therapeutic approaches. J Clin Oncol (2011) 0.91

Targeting CD20 in melanoma patients at high risk of disease recurrence. Mol Ther (2012) 0.89

Surgery for gastrointestinal malignant melanoma: experience from surgical training center. World J Gastroenterol (2010) 0.86

Cytokines, GM-CSF and IFNgamma administered by priming and post-chemotherapy cycling in recurrent ovarian cancer patients receiving carboplatin. J Transl Med (2006) 0.85

A phase II study of GM-CSF and rIFN-gamma1b plus carboplatin for the treatment of recurrent, platinum-sensitive ovarian, fallopian tube and primary peritoneal cancer. Gynecol Oncol (2009) 0.84

Randomized, Placebo-Controlled, Phase III Trial of Yeast-Derived Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients With No Evidence of Disease After Complete Surgical Resection of Locally Advanced and/or Stage IV Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E4697). J Clin Oncol (2015) 0.84

Granulocyte-macrophage colony-stimulating factor: another cytokine with adjuvant therapeutic benefit in melanoma? J Clin Oncol (2000) 0.84

Immune responses and therapeutic antitumor effects of an experimental DNA vaccine encoding human papillomavirus type 16 oncoproteins genetically fused to herpesvirus glycoprotein D. Clin Vaccine Immunol (2010) 0.83

Granulocyte-macrophage colony-stimulating factor alone or with dacarbazine in metastatic melanoma: a randomized phase II trial. Br J Cancer (2001) 0.83

Pilot study of intratumoral injection of recombinant heat shock protein 70 in the treatment of malignant brain tumors in children. Onco Targets Ther (2014) 0.83

Phase II clinical trial evaluating docetaxel, vinorelbine and GM-CSF in stage IV melanoma. Cancer Chemother Pharmacol (2011) 0.82

Immunotherapy for head and neck cancer: advances and deficiencies. Anticancer Drugs (2011) 0.82

GM-CSF and ipilimumab therapy in metastatic melanoma: Clinical outcomes and immunologic responses. Oncoimmunology (2015) 0.80

Treatment of prostate cancer: therapeutic potential of targeted immunotherapy with APC8015. Ther Clin Risk Manag (2008) 0.80

Local administration of granulocyte macrophage colony-stimulating factor induces local accumulation of dendritic cells and antigen-specific CD8+ T cells and enhances dendritic cell cross-presentation. Vaccine (2015) 0.79

Favorable alteration of tumor microenvironment by immunomodulatory cytokines for efficient T-cell therapy in solid tumors. PLoS One (2015) 0.79

Combination of IFN-α/Gm-CSF as a Maintenance Therapy for Multiple Myeloma Patients After Autologous Stem Cell Transplantation (ASCT): A Prospective Phase II Study. Clin Med Insights Oncol (2010) 0.78

Identification of Pre- and Post-Treatment Markers, Clinical, and Laboratory Parameters Associated with Outcome in Renal Cancer Patients Treated with MVA-5T4. Front Oncol (2013) 0.78

Adjuvant treatment of melanoma. ISRN Dermatol (2013) 0.78

Biological Effects of Anti-Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Antibody Formation in Patients Treated With GM-CSF (Sargramostim) as Adjuvant Therapy of Melanoma. Am J Clin Oncol (2014) 0.78

Stimulatory versus suppressive effects of GM-CSF on tumor progression in multiple cancer types. Exp Mol Med (2016) 0.77

In vivo effects of sequential granulocyte-macrophage colony stimulating factor (GM-CSF) and interleukin-2 (IL-2) on circulating dendritic cells (DC) in patients with surgically resected high risk cutaneous melanoma. J Clin Immunol (2006) 0.76

Tumor microenvironment and immune effects of antineoplastic therapy in lymphoproliferative syndromes. J Biomed Biotechnol (2010) 0.76

Critical analysis of an oncolytic herpesvirus encoding granulocyte-macrophage colony stimulating factor for the treatment of malignant melanoma. Oncolytic Virother (2014) 0.75

Systematic review of the use of granulocyte-macrophage colony-stimulating factor in patients with advanced melanoma. Cancer Immunol Immunother (2016) 0.75

Adjuvant Immunotherapy and Radiation in the Management of High-risk Resected Melanoma. Ochsner J (2010) 0.75

Biology of human cutaneous melanoma. Cancers (Basel) (2010) 0.75

Articles by these authors

(truncated to the top 100)

Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol (2001) 10.20

Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol (2001) 9.68

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol (1996) 9.68

Intercontinental spread of a multiresistant clone of serotype 23F Streptococcus pneumoniae. J Infect Dis (1991) 6.69

Naturally occurring auxin transport regulators. Science (1988) 6.20

Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol (1999) 5.95

Adenine arabinoside therapy of biopsy-proved herpes simplex encephalitis. National Institute of Allergy and Infectious Diseases collaborative antiviral study. N Engl J Med (1977) 5.02

High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol (2001) 4.84

High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol (2000) 4.60

Basal localization of the presumptive auxin transport carrier in pea stem cells. Science (1983) 4.59

Vidarabine versus acyclovir therapy in herpes simplex encephalitis. N Engl J Med (1986) 4.37

Acyclovir with and without prednisone for the treatment of herpes zoster. A randomized, placebo-controlled trial. The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Ann Intern Med (1996) 4.28

Pandemic influenza A(H1N1)v in New Zealand: the experience from April to August 2009. Euro Surveill (2009) 4.23

Breast-milk substitutes--a South African perspective urgently needed. S Afr Med J (1995) 3.98

A multifactorial analysis of melanoma. IV. Prognostic factors in 200 melanoma patients with distant metastases (stage III). J Clin Oncol (1983) 3.80

Antimicrobials for acute otitis media? A review from the International Primary Care Network. BMJ (1997) 3.72

Child resistant containers needed for liquid medications. BMJ (1993) 3.42

Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol (1991) 3.16

A multifactorial analysis of melanoma: prognostic histopathological features comparing Clark's and Breslow's staging methods. Ann Surg (1978) 2.94

Differential interactions of promoter elements in stress responses of the Arabidopsis Adh gene. Plant Physiol (1994) 2.92

Natural history of neonatal herpes simplex virus infections in the acyclovir era. Pediatrics (2001) 2.91

Vidarabine therapy of neonatal herpes simplex virus infection. Pediatrics (1980) 2.70

Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg (1996) 2.68

Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure. Circulation (1999) 2.68

A multifactorial analysis of melanoma. II. Prognostic factors in patients with stage I (localized) melanoma. Surgery (1979) 2.65

THE UTILIZATION OF INTRAVENOUSLY INJECTED SALT IN NORMALS AND IN PATIENTS WITH CUSHING'S SYNDROME BEFORE AND AFTER ADMINISTRATION OF DESOXYCORTICOSTERONE ACETATE. J Clin Invest (1944) 2.64

Herpes simplex encephalitis: vidarabine therapy and diagnostic problems. N Engl J Med (1981) 2.56

Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J Clin Oncol (2001) 2.47

Tumor thickness as a guide to surgical management of clinical stage I melanoma patients. Cancer (1979) 2.41

Diseases that mimic herpes simplex encephalitis. Diagnosis, presentation, and outcome. NIAD Collaborative Antiviral Study Group. JAMA (1989) 2.38

Safety and efficacy of high-dose intravenous acyclovir in the management of neonatal herpes simplex virus infections. Pediatrics (2001) 2.30

Cytogenetic features of human neuroblastomas and cell lines. Cancer Res (1981) 2.21

Recent skin self-examination and doctor visits in relation to melanoma risk and tumour depth. Br J Dermatol (2012) 2.20

Improved staging of node-negative patients with intermediate to thick melanomas (>1 mm) with the use of lymphatic mapping and sentinel lymph node biopsy. Ann Surg Oncol (2001) 2.19

Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res (1990) 2.16

Low levels of zinc in hair, anorexia, poor growth, and hypogeusia in children. Pediatr Res (1972) 2.12

A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis. Neurology (2003) 2.10

A comparison of prognostic factors and surgical results in 1,786 patients with localized (stage I) melanoma treated in Alabama, USA, and New South Wales, Australia. Ann Surg (1982) 2.09

Cellular DNA content as a predictor of response to chemotherapy in infants with unresectable neuroblastoma. N Engl J Med (1984) 2.09

A multifactorial analysis of melanoma: III. Prognostic factors in melanoma patients with lymph node metastases (stage II). Ann Surg (1981) 2.09

Tissue-shrinkage correction factor in the calculation of prostate cancer volume. Am J Surg Pathol (1996) 2.06

Long-term results of a prospective surgical trial comparing 2 cm vs. 4 cm excision margins for 740 patients with 1-4 mm melanomas. Ann Surg Oncol (2001) 2.06

The Aristotle score: a complexity-adjusted method to evaluate surgical results. Eur J Cardiothorac Surg (2004) 2.05

Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Engl J Med (1991) 1.98

MAGNESIUM PARTITION STUDIES IN GRAVES' DISEASE AND IN CLINICAL AND EXPERIMENTAL HYPOTHYROIDISM. J Clin Invest (1941) 1.89

Relapse and rehospitalization during maintenance treatment of schizophrenia. The effects of dose reduction and family treatment. Arch Gen Psychiatry (1997) 1.86

Hearing loss in children and young adults receiving cisplatin with or without prior cranial irradiation. J Clin Oncol (1989) 1.85

3-Nitrotyrosine in the proteins of human plasma determined by an ELISA method. Biochem J (1998) 1.83

Herpes simplex encephalitis. Clinical Assessment. JAMA (1982) 1.83

Changing presentation of herpes simplex virus infection in neonates. J Infect Dis (1988) 1.76

A model to predict the histopathology of human stroke using diffusion and T2-weighted magnetic resonance imaging. Stroke (1995) 1.75

Conformation and molecular mechanisms of carriers and channels. Ann N Y Acad Sci (1975) 1.74

A randomized trial to improve self-management practices of adults with asthma. Arch Intern Med (1990) 1.67

The prognostic significance of ulceration of cutaneous melanoma. Cancer (1980) 1.66

Radiotherapy improves the outlook for patients older than 1 year with Pediatric Oncology Group stage C neuroblastoma. J Clin Oncol (1991) 1.66

Prophylactic lymph node dissection in clinical stage I cutaneous malignant melanoma: results of surgical treatment in 1319 patients. Br J Surg (1982) 1.62

Cloning, sequencing and expression of subtilisin Carlsberg from Bacillus licheniformis. Nucleic Acids Res (1985) 1.61

Phase specific analysis of herpes zoster associated pain data: a new statistical approach. Stat Med (2001) 1.60

Norwegian scabies and a toxic shock syndrome toxin 1-producing strain of Staphylococcus aureus endocarditis in a patient with trisomy 21. Clin Infect Dis (1998) 1.60

Low-density lipoproteins inhibit endothelium-dependent relaxation in rabbit aorta. Nature (1987) 1.60

Homozygous deletions within human chromosome band 9p21 in melanoma. Proc Natl Acad Sci U S A (1992) 1.58

The prognostic significance of autologous bone marrow transplant in advanced neuroblastoma. J Clin Oncol (1991) 1.52

A new American Joint Committee on Cancer staging system for cutaneous melanoma. Cancer (2000) 1.52

Phase II investigational window using carboplatin, iproplatin, ifosfamide, and epirubicin in children with untreated disseminated neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol (1994) 1.51

High-dose cisplatin and dacarbazine in the treatment of metastatic melanoma. J Natl Cancer Inst (1990) 1.51

Predictors of sun exposure in adolescents in a southeastern U.S. population. J Adolesc Health (1996) 1.50

Oral acyclovir therapy accelerates pain resolution in patients with herpes zoster: a meta-analysis of placebo-controlled trials. Clin Infect Dis (1996) 1.50

Posterior lenticonus: clinical patterns and genetics. J Pediatr Ophthalmol Strabismus (1993) 1.49

Cranial irradiation after surgical excision of brain metastases in melanoma patients. Ann Surg Oncol (1996) 1.48

A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). Blood (1995) 1.47

Tublin: nucleotide binding and enzymic activity. J Mol Biol (1974) 1.46

A multifactorial analysis of prognostic factors in patients with liver metastases from colorectal carcinoma. J Clin Oncol (1983) 1.46

A flow cytometric method to estimate the precursor frequencies of cells proliferating in response to specific antigens. J Immunol Methods (1999) 1.46

Second-look laparotomy and salvage therapy: a research modality only? Gynecol Oncol (1992) 1.45

A prospective phase II clinical trial of continuous FUDR regional chemotherapy for colorectal metastases to the liver using a totally implantable drug infusion pump. Ann Surg (1983) 1.45

Electrophoretic distribution of serum proteins of normal and an arthritic white-tailed deer (Odocoileus virginianus). Am J Vet Res (1969) 1.41

Administration of oral acyclovir suppressive therapy after neonatal herpes simplex virus disease limited to the skin, eyes and mouth: results of a phase I/II trial. Pediatr Infect Dis J (1996) 1.41

Prognostic histopathological factors in malignant melanoma. Pathology (1985) 1.39

The feminisation of medical practice. Lancet (1990) 1.39

Transformation of Aspergillus giganteus to hygromycin B resistance. Curr Genet (1990) 1.38

A novel human type II cytokeratin, K6hf, specifically expressed in the companion layer of the hair follicle. J Invest Dermatol (1998) 1.37

Percutaneous balloon valvotomy for patients with severe mitral stenosis. Circulation (1987) 1.37

Isolation of the ornithine-delta-aminotransferase cDNA and effect of salt stress on its expression in Arabidopsis thaliana. Plant Physiol (1998) 1.31

Relationships between socioeconomic status and race-specific cervical cancer incidence in the United States, 1973-1992. J Health Care Poor Underserved (1998) 1.31

Consistent N-myc copy number in simultaneous or consecutive neuroblastoma samples from sixty individual patients. Cancer Res (1987) 1.31

Prediction of pathology and survival by FDG PET in gliomas. J Neurooncol (2003) 1.29

Is laparoscopic surgery applicable to complicated colonic diverticular disease? Surg Endosc (1997) 1.27

Early vidarabine therapy to control the complications of herpes zoster in immunosuppressed patients. N Engl J Med (1982) 1.27

Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. J Clin Oncol (1996) 1.27

DNA-mediated genetic correction of thiamineless Arabidopsis thaliana. Nature (1974) 1.25

Polymorphism of alcohol dehydrogenase in Arabidopsis thaliana (L.) Heynh.: genetical and biochemical characterization. Biochem Genet (1984) 1.25

In vivo description of dendritic cells in human renal cell carcinoma. J Urol (1999) 1.23

Interferons in the treatment of human cancer. J Clin Oncol (1984) 1.22

Two Feedback-Insensitive Enzymes of the Aspartate Pathway in Nicotiana sylvestris. Plant Physiol (1992) 1.21

Identification of the flagellar proteins of Chlamydomonas reinhardii. Exp Cell Res (1970) 1.21

World's best practice in tobacco control. Tob Control (2000) 1.19

Sequence analysis of two null-mutant alleles of the single Arabidopsis Adh locus. Mol Gen Genet (1990) 1.19

Prognostic significance of DNA aneuploidy in stage I cutaneous melanoma. Ann Surg (1988) 1.19

Duplex microtubule is a new form of tubulin assembly induced by polycations. Nature (1975) 1.18

Adenocarcinoma of the cervix. I. Clinical evaluation and pathologic features. Am J Obstet Gynecol (1981) 1.18